Berliner Tageblatt - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
CMSC -1.22% 18.91 $
JRI -1% 10.98 $
BCC -1.08% 65.66 $
RIO -0.69% 79.5 $
RYCEF 0.85% 17.74 $
NGG -1.86% 82.74 $
RBGPF 0% 75.65 $
VOD -0.43% 15.245 $
RELX -2.16% 39.585 $
CMSD -1.37% 18.605 $
BP -0.27% 44.8 $
BCE -0.11% 22.105 $
GSK -2.19% 49.33 $
AZN -0.84% 182.49 $
BTI -4.38% 59.505 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report / Photo: ©

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

B.Shevchenko--BTB